Oncoshot Enters Collaboration Agreement With Omico (Australian Genomic Cancer Medicine Centre)

Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of Oncoshot, and Prof David Thomas, CEO of Omico and head of Genomic Cancer Medicine at the Garvan Institute.
Diane Galistan
19 July 2022

Oncoshot Receives Funding To Expand Cancer Data Sharing Capabilities For Hospitals and Industry

Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors.
Diane Galistan
13 July 2022

Oncoshot Enters Into MOU With Singapore Clinical Research Institute

Oncoshot has signed a memorandum of understanding with the Singapore Clinical Research Institute (SCRI), the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS). The signing event held last Wednesday was witnessed by guest-of-honour Minister for Health Mr Ong Ye Kung.
Diane Galistan
13 April 2022

Milltrust Ventures to Invest in First-In-Class Health Tech Platform Oncoshot

SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company founded in Singapore.
Diane Galistan
22 March 2022

Oncoshot launches InSite Feasibility and partners AstraZeneca to streamline recruitment process for cancer clinical trials

AstraZeneca will tap into Oncoshot’s data analytic capabilities of InSite Feasibility to introduce more relevant and innovative cancer clinical trials to Singapore.  
Cara Yap
24 September 2021

Dr Raghav Sundar: The precision oncology wave in Singapore is coming

Public and private sectors in Singapore are harnessing genomic data through technologies such as Artificial Intelligence to advance the field of precision oncology.
Cara Yap
21 September 2021

Dr Toh Chee Keong: zimberelimab trialled in new combination immunotherapy for PD-L1 positive metastatic non small cell lung cancer

Similar PD-1 inhibitors have been shown to improve the five-year survival rate of patients with advanced non-small cell lung cancer.
Cara Yap
30 July 2021

Breast cancer rehabilitation: post mastectomy physical therapy and more

Experts including Dr Mothi Babu Ramalingam from Singapore General Hospital weighed in on breast cancer rehabilitation options in Singapore, including TCM.
26 July 2021

Prof Pierce Chow: ELEGANCE study explores cutting-edge methods to detect liver cancer early and more accurately

The multi-centre Singapore study offers active surveillance to patients at high risk of developing liver cancer, with the aim of developing more accurate miRNA diagnostics for early HCC.
Cara Yap
5 July 2021

Dr Choo Su Pin: New study explores treating advanced-stage HCC patients with Toripalimab and Bevacizumab

The therapy being trialled combines Toripalimab, an anti-PD1 immunotherapy drug developed in China, together with Bevacizumab.
Cara Yap
24 June 2021

Stage 3 breast cancer survivor: mental health support is crucial in recovery

Tech professional Amy Neary drew on emotional support from her family, friends and Singapore’s Breast Cancer Foundation to cope with the rigorous treatments and surgeries, plus the toll they took on her mental well-being.
Cara Yap
14 May 2021

Oncoshot named winner at Singapore Business Review National Business Awards 2021

Oncoshot was recognised as winner for the Health Products & Services category, for its commitment to elevate cancer treatment through technology.
Cara Yap
7 May 2021

Dr Tira Tan: HERBAL trial explores improving cancer survivors’ quality of life through TCM

The Phase II, randomised, double-blinded, placebo-controlled trial, which is being conducted at NCCS, evaluates the safety and efficacy of the Xiang Bei Yang Rong Tang decoction in reducing cancer related fatigue.
Cara Yap
3 May 2021

Dr Choo Su Pin on ongoing Phase III EMERALD-1 study for cancer patients with intermediate stage HCC

The global study explores the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE with durvalumab plus bevacizumab therapy.
Cara Yap
7 April 2021

Oncoshot in TechNode Global feature on health-tech start-ups driving innovation in the face of Covid-19

The regional media outlet highlighted Oncoshot's contributions in fostering a more collaborative, data-driven cancer clinical trial landscape.
Cara Yap
11 March 2021

PRECISE CURATE.AI trial: Dr Dean Ho and Dr Raghav Sundar on pilot study exploring guided dosing with XELOX, XELIRI and single agent capecitabine to treat solid tumours

The Phase I and II single-arm pilot study with multiple cohorts of patient populations harnesses AI for personalised guidance of an individual’s dose modulations based only on his/her data. It aims to re-look at the way oncology clinical trials are designed.
Cara Yap
1 March 2021

How to ensure successful cancer clinical trial enrolment

Tech-powered solutions such as data-driven pre-screening tools can enable more accurate feasibility studies, thus improving cancer clinical trial enrolment rates.
Cara Yap
25 February 2021

Liver cancer trial: Dr Toh Han Chong on ongoing study using Atezolizumab plus Bevacizumab to lower recurrence risk in patients with hepatocellular carcinoma

He leads a Phase III, randomised, open-label study of Atezolizumab plus Bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation.
Cara Yap
7 January 2021

Breast cancer trial: Dr Yap Yoon Sim on why ongoing clinical trial is significant for patients with PIK3CA-mutant, hormone receptor-positive, Her2-negative, locally advanced or metastatic breast cancer

The phase III, randomised, double-blind, placebo-controlled study evaluates the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients who meet the specific trial criteria.
Cara Yap
11 December 2020

Oncoshot wins at Technode Global Origin Innovation Awards 2020

Oncoshot won in the Healthtech category of the Startup Awards, which honour regional startups that embody the spirit of innovation and entrepreneurship.
Cara Yap
19 November 2020